



Restriction Map of pI κ B-EGFP. All sites shown are unique.

Description:

The pI κ B-EGFP Vector encodes the I κ B-EGFP Signaling Probe, which is a fusion of enhanced green fluorescent protein (EGFP) and I κ B. I κ B is an inhibitor of NF κ B, a transcription factor involved in the immune response and inflammatory diseases. When the NF κ B pathway is inactive, I κ B and NF κ B exist as an inactive complex in the cytosol. Upon stimulation, I κ B is degraded. In cells transfected with pI κ B-EGFP, degradation of the I κ B-EGFP fusion protein is observed as a decrease in EGFP fluorescence (1). The I κ B-EGFP Signaling Probe is constitutively expressed and resides in the cytosol.

EGFP is a red-shifted, human codon-optimized variant of GFP (2–6) that has been engineered for brighter fluorescence and higher expression in mammalian cells. Its excitation maximum is 488 nm and emission maximum is 509 nm. For more information on the properties of EGFP, please refer to the BD Living Colors™ User Manual (PT2040-1) included with the vector.

Expression of the I κ B-EGFP is driven by the human CMV immediate-early promoter. The SV40 poly-A sequence directs proper processing of the 3' end of the fusion construct. The vector backbone also contains an SV40 origin for replication in mammalian cells expressing the SV40 T-antigen. A neomycin resistance cassette (Neo^r) allows kanamycin selection in *E. coli* and neomycin (G418) selection in eukaryotic cells. This cassette consists of the SV40 early promoter, the neomycin/kanamycin resistance gene of Tn5, and poly-A signals from the Herpes simplex virus thymidine kinase (HSV TK) gene. The vector backbone also provides a pUC origin of replication for propagation in *E. coli* and an f1 origin for single-stranded DNA production.

Use:

The I κ B-EGFP Signaling Probe can be used to monitor activation of the NF κ B signalling pathway by observing changes in EGFP fluorescence. EGFP can be detected by fluorescence microscopy or by flow cytometry. No antibody staining or fixation is necessary.

This vector is not intended for use as a cloning vector; however, there are sites flanking the EGFP and I κ B coding regions for subcloning these sequences into other expression vectors. The vector can be transfected into mammalian cells using any standard method. If required, stable transformants can be selected using G418 (7).

Location of Features:

- Human cytomegalovirus (CMV) immediate early promoter: 1–589
Enhancer region: 59–465; TATA box: 554–560
Transcription start point: 583
C→G mutation to remove *Sac* I site: 569
- I κ B gene: 655–1605
- Enhanced green fluorescent protein gene: 1621–2337
Start codon (ATG): 1621–1623
Insertion of Val at position 2: 1624–1626
GFPmut1 chromophore mutations (Phe-64 to Leu; Ser-65 to Thr): 1813–1818
His-231 to Leu mutation (A→T): 2315
- SV40 early mRNA polyadenylation signal
Polyadenylation signals: 2494–2499 & 2523–2528; mRNA 3' ends: 2532 & 2544
- f1 single-strand DNA origin: 2591–3046 (Packages the noncoding strand of I κ B-EGFP)
- Bacterial promoter for expression of Kan^r gene
–35 region: 3108–3113; –10 region: 3131–3136
Transcription start point: 3143
- SV40 origin of replication: 3387–3522
- SV40 early promoter
Enhancer (72-bp tandem repeats): 3220–3291 & 3292–3363
21-bp repeats: 3367–3387, 3388–3408 & 3410–3430
Early promoter element: 3443–3449
Major transcription start points: 3439, 3477, 3483 & 3488
- Kanamycin/neomycin resistance gene
Neomycin phosphotransferase coding sequences:
Start codon (ATG): 3571–3573; stop codon: 4363–4365
G→A mutation to remove *Pst* I site: 3753
C→A (Arg to Ser) mutation to remove *Bss*H II site: 4099
- Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal
Polyadenylation signals: 4601–4606 & 4614–4619
- pUC plasmid replication origin: 4950–5593

Primer Locations:

- EGFP-N Sequencing Primer (#6479-1): 1687–1666
- EGFP-C Sequencing Primer (#6478-1): 2274–2295
- Suitable host strains: DH5 α , HB101, and other general purpose strains. Single-stranded DNA production requires a host containing an F plasmid such as JM109 or XL1-Blue.
- Selectable marker: plasmid confers resistance to kanamycin (50 μ g/ml) to *E. coli* hosts.
- *E. coli* replication origin: pUC
- Copy number: \approx 500
- Plasmid incompatibility group: pMB1/ColE1

References:

1. Mercury EGFP Signaling Probes (July 1999) *CLONTECHniques* **XIV**(3):22–24.
2. Prasher, D. C., *et al.* (1992) *Gene* **111**:229–233.
3. Chalfie, M., *et al.* (1994) *Science* **263**:802–805.
4. Inouye, S. & Tsuji, F. I. (1994) *FEBS Letters* **341**:277–280.
5. Cormack, B., *et al.* (1996) *Gene* **173**:33–38.
6. Haas, J., *et al.* (1996) *Curr. Biol.* **6**:315–324.
7. Gorman, C. (1985) In *DNA Cloning: A Practical Approach, Vol. II*, Ed. Glover, D. M. (IRL Press, Oxford, UK) pp. 143–190.

Note: The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by BD Biosciences Clontech. This vector has not been completely sequenced.

Notice to Purchaser

Use of BD Biosciences Clontech's Living Colors™ products containing DNA sequences coding for mutant *Aequorea victoria* green fluorescent protein (GFP) variants or proteins thereof requires a license from Amersham Biosciences under U.S. Patent Nos. 5,625,048; 5,777,079; 6,054,321 and other pending U.S. and foreign patent applications. In addition, certain BD Biosciences Clontech products are made under U.S. Patent No. 5,804,387 licensed from Stanford University.

Not-For-Profit research institutes or entities are granted an automatic license with the purchase of this product for use in non-commercial internal research purposes, the terms of which are disclosed in detail in the license that accompanies the shipment of this product. Such license specifically excludes the right to sell or otherwise transfer this product or its components to third parties.

For-Profit research institutes or entities must obtain a license from Amersham Biosciences. E-mail: gfp@amershambiosciences.com

Please contact BD Biosciences Clontech directly for any other assistance, including purchasing and technical support. All companies and institutions purchasing Living Colors™ products will be included in a quarterly report to Aurora Biosciences, as required by the BD Biosciences Clontech/Aurora Biosciences license agreement.

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes nor is it intended for human use. BD Biosciences Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of BD Biosciences Clontech.

© 2002, Becton, Dickinson and Company